NEW ORLEANS, April 27, 2018 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that theyhave until May 28, 2018 to file lead plaintiff applications in a securities class action lawsuit against Solid Biosciences Inc. (NasdaqGS: SLDB), if they purchased the Company's shares between January
Solid Biosciences investors should visit us at https://www.claimsfiler.com/cases/view-solid-biosciences-inc-securities-litigation or call to speak to our claim center toll-free at (844) 367-9658.
About the Lawsuit
Solid Biosciences and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On January 30, 2018, a report co-authored by a former scientific advisor of the Company revealed risks of high systemic dosing using the Company's delivery system, AAV or adeno-associated virus, for its lead drug candidate SGT-001. Then, on March 14, 2018, the Company disclosed a clinical hold placed on the SGT-001 trial by the FDA relating to adverse events.
On this news, the price of Solid Biosciences' shares plummeted over 60% to $9.32/share on March 15, 2018.
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. ClaimsFiler's team of experts monitor the securities class action landscape and cull information from a variety of sources to ensure comprehensive coverage across a broad range of financial instruments.
To learn more about ClaimsFiler, visit www.claimsfiler.com.
View original content:http://www.prnewswire.com/news-releases/solid-biosciences-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-of-lead-plaintiff-deadline-in-class-action-lawsuit-against-solid-biosciences-inc---sldb-300638309.html
Subscribe to our Free Newsletters!
Osteolysis refers to breaking down of bone tissue. Bone loss occurs due to resorption of bone by ...
Patisiran injection, recently approved by FDA to treat polyneuropathy, a disease that causes ...
Dysgraphia or disorder of written expression is a childhood learning disorder marked by poor ...View All